8-K: Merck to Acquire Terns Pharmaceuticals for $6.7 Billion

Merck announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, valuing the company at approximately $6.7 billion.

Summary

• Merck, through a subsidiary, will acquire Terns Pharmaceuticals, Inc. for $53.00 per share in cash.
• The total equity value of the acquisition is approximately $6.7 billion, or $5.7 billion net of acquired cash.
• This offer represents a premium of approximately 31% to Terns' 60-day volume-weighted average stock price and 42% to its 90-day volume-weighted average stock price as of March 24, 2026.
• The acquisition is primarily driven by Terns' lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia (CML).
• TERN-701 is currently in Phase 1/2 development (CARDINAL trial) for patients with Philadelphia chromosome-positive (Ph+) CML who have previously experienced treatment failure, suboptimal response, or intolerance to other TKIs.
• The U.S. FDA granted Orphan Drug Designation for TERN-701 for the treatment of CML in March 2024.
• The transaction has been unanimously approved by Terns' Board of Directors, which recommends stockholders tender their shares.
• The acquisition is structured as a tender offer followed by a merger, subject to conditions including a majority of Terns' shares being tendered and expiration of the HSR Act waiting period.
• The transaction is expected to close in the second quarter of 2026 and will be accounted for as an asset acquisition by Merck, resulting in a charge of approximately $5.8 billion ($2.35 per share) in Q2 and full year 2026 GAAP and non-GAAP results.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development for Terns shareholders, offering a substantial premium and a clear exit strategy. The acquisition by a major pharmaceutical company like Merck validates Terns' lead asset, TERN-701, and its potential in the CML market.

Positives

• Terns shareholders will receive a significant cash premium of 31% over the 60-day VWAP and 42% over the 90-day VWAP, providing immediate and substantial value.
• The acquisition by Merck, a global biopharmaceutical leader, provides TERN-701 with extensive resources and expertise for continued development and potential commercialization.
• TERN-701 has shown promising clinical activity in Phase 1/2 trials, including encouraging rates of major and deep molecular response in CML patients, even those with high disease burden and prior TKI treatment.
• The safety profile of TERN-701 appears favorable, with a low incidence of severe adverse events, no clinically meaningful changes in blood pressure, and low rates of lipase elevation.
• The FDA's Orphan Drug Designation for TERN-701 highlights its potential to address an unmet medical need in CML.

Negatives

• Terns Pharmaceuticals will cease to exist as an independent publicly traded company, ending its standalone growth potential.
• Shareholders who believe TERN-701's long-term value exceeds the $53.00 per share offer price may view the acquisition as undervaluing the asset.

Risks

• Risks related to the timing of the Offer, the Merger, and other Transactions, or that they may not be completed at all.
• Uncertainty whether sufficient Terns stockholders will tender their Shares in the Offer.
• The risk that competing offers or acquisition proposals will be made.
• The possibility that various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including governmental entities prohibiting, delaying, or refusing approval.
• Risks associated with acquisitions, such as disruption to Terns' business and difficulty maintaining relationships with employees and business partners due to the announcement and pendency of the Transactions.
• Risks related to diverting management's attention from Terns' ongoing business operations.
• The risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.
• Unanticipated delays in or negative results from Terns' clinical studies and other risks related to clinical development.
• Delays in or unanticipated action by regulatory authorities.
• General industry conditions and competition, economic factors, pharmaceutical industry regulation, healthcare legislation, technological advances, and manufacturing difficulties.

Future Outlook

Merck anticipates that the acquisition will expand its hematology pipeline with TERN-701, a potential best-in-class candidate for CML, further diversifying and strengthening its oncology position. Terns' management believes the transaction will advance TERN-701 by leveraging Merck's expertise and resources. The transaction is expected to close in the second quarter of 2026.

Management Comments

• Robert M. Davis, chairman and chief executive officer, Merck: "The acquisition of Terns builds on our growing presence in hematology with TERN-701, a potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia. This transaction further diversifies and strengthens our position in oncology as we continue to look for opportunities to broaden our portfolio into other therapeutic areas."
• Amy Burroughs, chief executive officer, Terns: "This acquisition reflects our teams deep commitment to innovation in oncology and developing high impact medicines. By working together, we will advance TERN-701, leveraging the deep expertise and significant resources at Merck, a global biopharmaceutical leader with a proven track record of delivering cancer breakthroughs for patients who need them most. I am immensely proud of the Terns team and our work towards making a difference for people living with CML. Finally, we extend our heartfelt thanks to the investigators, patients, and community advocates whose dedication and support make the development of TERN-701 possible."
• Dr. Dean Y. Li, president, Merck Research Laboratories: "Based on early clinical evidence, TERN-701, a novel allosteric BCR::ABL1 inhibitor, may have the potential to provide a meaningfully differentiated option for certain patients living with CML."

Industry Context

StockSavvy.ai notes that this acquisition underscores the pharmaceutical industry's continued focus on expanding oncology pipelines, particularly in areas with unmet needs like CML. The move by Merck to acquire Terns and its lead candidate, TERN-701, demonstrates a strategic effort to enhance its hematology portfolio and leverage innovative therapies. The CML market, while having existing treatments, still seeks novel, well-tolerated options with faster and deeper molecular responses, which TERN-701 aims to provide. This transaction reflects a broader trend of larger pharmaceutical companies acquiring clinical-stage biotechs to gain access to promising drug candidates and intellectual property, rather than developing them in-house from early stages.

Comparison to Industry Standards

• The CML treatment landscape has been transformed by BCR::ABL1 tyrosine kinase inhibitors (TKIs) over the past 25 years. TERN-701, as a novel allosteric BCR::ABL1 TKI, aims to improve upon existing treatments.
• The filing highlights TERN-701's promising activity, with encouraging rates of major molecular response and deep molecular response observed by week 24, including in patients with high disease burden who previously received multiple lines of therapy, including other allosteric TKIs. This suggests a potentially differentiated profile compared to current standard-of-care TKIs like imatinib (Gleevec), nilotinib (Tasigna), dasatinib (Sprycel), bosutinib (Bosulif), and ponatinib (Iclusig), especially for patients with resistance or intolerance.
• The reported low incidence of severe adverse events, no clinically meaningful changes in blood pressure, and low rates of lipase elevation for TERN-701 could represent an improvement in tolerability compared to some existing TKIs, which can have significant side effects (e.g., cardiovascular events with nilotinib, pleural effusions with dasatinib, pancreatitis/lipase elevation with ponatinib).
• The acquisition premium of 31-42% is within the typical range for biotech acquisitions, reflecting the value placed on a promising clinical-stage asset with Orphan Drug Designation and positive early clinical data in a competitive but still needy therapeutic area.

Corporate Governance

Legal Proceedings

• The filing mentions the risk of stockholder litigation in connection with the Transactions, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive $53.00 per share in cash, representing a significant premium and a definitive return on investment.
• Employees: Continuing employees will receive comparable base salary, short-term cash incentives, and aggregate benefits for one year post-acquisition, with service credit for eligibility and vesting in Merck's plans. Equity awards will be cashed out.
• Customers/Patients: The acquisition by Merck is expected to accelerate the development and potential commercialization of TERN-701, potentially benefiting CML patients by bringing a new treatment option to market faster.
• Management: Current Terns management will be replaced by Merck's subsidiary management post-merger, though specific roles for current Terns executives within Merck are not detailed.
• Regulatory Authorities: The transaction is subject to review and approval by antitrust authorities (e.g., HSR Act) and ongoing regulatory oversight for TERN-701's clinical development.

Next Steps

• Merck's subsidiary will commence a tender offer to purchase all outstanding shares of Terns Pharmaceuticals within 10 business days of March 24, 2026.
• Terns will file a Solicitation/Recommendation Statement on Schedule 14D-9 concurrently with the tender offer commencement.
• The tender offer will initially be open for 20 business days, subject to extensions under certain conditions.
• Following the consummation of the tender offer, a merger will occur, with Terns becoming a wholly-owned subsidiary of Merck.
• Terns' equity incentive plans and ESPP will be terminated at or prior to the Effective Time, with outstanding awards converted to cash or exercised.
• The transaction is expected to close in the second quarter of 2026, subject to regulatory approvals (e.g., HSR Act clearance) and other customary closing conditions.
• Merck will hold an investor call on March 25, 2026, at 8 a.m. EDT to discuss the proposed transaction.

Key Dates

Recommendation

For Terns Pharmaceuticals shareholders, the definitive agreement to be acquired by Merck at $53.00 per share represents a substantial and immediate premium over recent trading prices. The offer provides a clear, all-cash exit, eliminating market risk associated with clinical development and future financing. Given the unanimous board approval and the customary nature of the closing conditions, the probability of deal completion is high. Therefore, a seasoned investor or institution would view this as a strong buy opportunity for Terns shares up to the offer price, anticipating the realization of the acquisition value.

Keywords

Terns Pharmaceuticals, Merck, Acquisition, Merger, TERN-701, Chronic Myeloid Leukemia, CML, BCR::ABL1 inhibitor, Tyrosine Kinase Inhibitor, TKI, Oncology, Hematology, Pharmaceuticals, Biotechnology, Tender Offer, Orphan Drug Designation